We’re delighted to add a summary of a presentation by Dr Mary-Ann Anderson on optimal sequencing of novel agents in patients with chronic lymphocytic leukaemia. The discussion covers the impact of novel therapies on the treatment landscape in Australia with data from randomised controlled trials and real-world evidence.
Dr Mary-Ann Anderson is a haematologist at the Royal Melbourne Hospital and Peter MacCallum Cancer Centre.
Please login below to download this issue (PDF)